
SME IPO
Himalaya Nutravedics India IPO
Prices in INR · Times in IST
GMP updated: 29 Sep 2026, 08:24 AM IST
- Price band
- ₹100 – ₹106
- Application estimate
- ₹2,54,4002 lot(s) · 1200 sh
- GMP · unofficial
- ₹0 (0%)
- Est. listing price
- ₹106Issue price + GMP
- Issue size
- ₹26.5 Cr
- Total subscription
- 2.41×
GMP trend & intraday history
Hover or tap on the chart to inspect a reading. Dates use calendar spacing; large gaps are not connected.
- High in this view
- ₹0 (₹0)
- Low in this view
- ₹0 (₹0)
- Reference issue price
- ₹106
- Readings in this view
- 11
- Subject to sauda
- 0
Issue at a glance
IPO timetable & schedule
Subscription by investor category
Source updated: 17 Nov 2026, 04:21 PM IST
Overall Demand: 2.41×Mainboard figures are consolidated. NSE and BSE demand is not added together. Rupee demand is calculated from bid shares and the cap price; it is not an exchange-published amount. Application source: boa.
QIB funding cost illustration
Arithmetic for a fully funded institutional bid over 7 days; not a recommendation or a retail return estimate.
- Days
- 7
- Interest Rate
- Not published
- Cost Per Share
- 106
Day-wise subscription history
One snapshot near each bidding day’s close. This is not a continuous intraday series.
Plan your application
SME individual applications use 2 lots and must exceed ₹2 lakh under the NSE process effective July 2025.
The source application tiers need verification: a one-lot retail tier does not match the newer SME process. Use the rule-based estimate above and confirm the offer document.
One lot: ₹1,27,200 · Allocation is not guaranteed. Broker cut-off times may differ.
Source-published application tiers
Before you place an IPO application
- Read the issue. Check the offer document, business risks, price band and your application category.
- Apply through your broker or bank. Use your existing broker’s IPO section or your bank’s ASBA facility. This page does not submit a bid.
- Check the payment step. If using UPI, confirm the mandate in your UPI app and check that the funds are blocked. A saved bid alone is not confirmation.
- Track what happens next. Keep your application number. Use the registrar’s official page for allotment and the published timeline for refunds, demat credit and listing.
GMP return scenario
What could this amount look like?
GMP-based scenario · Not a forecast
Assumes all requested shares are allotted and listing equals issue price + GMP. Actual allotment, listing price, fees and taxes can change the result.
Your IPO progress
Keep your own record of this IPO. Statuses are entered by you, not verified with a broker or registrar. Saved on this browser for your signed-in account; not synced across devices.
IPO reservation & shares offered
Shares offered by category
Category-wise allocation percentages follow SEBI ICDR norms as stated in the offer document.
Promoter holding & ownership
Rohit Asawa, Divya Asawa, Chanda Asawa and Rama Raju Penmatsas
Anchor investors & allocations
- Anchor entities
- 0
- Total allocation (₹ crore)
- 0
- Mutual fund allottees
- 0
- Official allocation document
- Anchor document: not published
Investor allocations
No data has been published for this section yet.
By fund house
No data has been published for this section yet.
Financials & valuation
Figures in Rs. Crore · Changes compare matching annual period-end dates only.
- Profit After Tax
- 7.39Latest: 31 Mar 2026+231.39% YoY · Prior 2.23
- EBITDA
- 8.1Latest: 31 Mar 2026+170.9% YoY · Prior 2.99
- Total Borrowing
- 5.13Latest: 31 Mar 2026+191.48% YoY · Prior 1.76
Rs. Crore
Key valuation & financial KPIs
- P/E Ratio
- 12.63
- EPS (₹)
- 8.39
- RoE
- 63.87%
- RoCE
- 36.41%
- RoNW
- 45.12%
- PAT Margin
- 17.16%
- EBITDA Margin
- 18.82%
- Debt / Equity
- 0.31
- NAV (₹)
- 26.70
What does the company do?
Himalaya Nutravedics India Limited was started in June 2022. It is a Hyderabad based company that formulates, manufactures and markets Ayurvedic and nutraceutical products. Its products come in several forms, including softgel capsules, tablets, medicated oils, liquid orals, hardgel capsules and protein powders. Being able to make all of these in one place is unusual for a company of this size, because each dosage form needs its own line and approvals. Its products cover therapeutic areas such as digestive health, immunity, metabolic health and pain management. It sells in two ways. Its own branded products are marketed through healthcare practitioners rather than through mass advertising, so doctors recommending the product is what drives sales. Alongside that it manufactures on a third party contract basis for other brands. It has expanded to 17 states and one union territory in India. Its manufacturing facility is in Hyderabad, Telangana and holds ISO 22000:2018, ISO 9001:2015 and WHO-GMP certification. As on 30 April 2026 it had 80 employees.
More about the business
Himalaya Nutravedics India Limited is a Hyderabad-based Ayurvedic and nutraceutical manufacturer making softgel capsules, tablets, medicated oils, liquid orals and protein powders across digestive, immunity, metabolic and pain management categories. It sells through healthcare practitioners and also does third-party contract manufacturing across 17 states.
Where will the money go?
Strengths & risks
Business strengths
- Sales have tripled in two years, from Rs 14.43 crore in FY2024 to Rs 21.00 crore in FY2025 and Rs 43.12 crore in FY2026.
- Profit has grown from Rs 0.43 crore in FY2024 to Rs 2.23 crore in FY2025 and Rs 7.39 crore in FY2026.
- The margin is high for a small manufacturer, with a PAT margin of 17.16% and an EBITDA margin of 18.82%.
- Return ratios are very strong, with RoNW of 45.12% and RoCE of 36.41%.
- Debt is low. Total borrowing was Rs 5.13 crore against a net worth of Rs 16.38 crore, a debt to equity ratio of only 0.31.
- The issue is priced at about 12.63 times earnings on an EPS of Rs 8.39.
- It can make several dosage forms in one facility, from softgels and tablets to oils, liquids and powders, which lets it serve a wider set of contract manufacturing customers.
- The Hyderabad facility holds WHO-GMP certification along with ISO 22000:2018 and ISO 9001:2015, which matters for both export and contract work.
Risks to understand
- The company is very young. It was started only in June 2022, so it has around four years of history and has not been tested through a difficult period.
- The growth is from a very small base. Sales tripled and profit rose about seventeen times in two years, which cannot be assumed to continue.
- Rs 7.50 crore of the Rs 26.5 crore issue goes into business development and digital marketing. That is a running cost rather than an asset, and it will need to be spent again.
- Sales depend on healthcare practitioners recommending the products. That relationship has to be maintained continuously and can be won away by competitors.
- The whole business runs from one facility in Hyderabad, so there is single location risk.
- Ayurvedic and nutraceutical products are a crowded category with low barriers to entry and many small manufacturers.
- The contract manufacturing part of the business earns a lower margin than selling its own brands.
- Promoter holding will come down from 95.14% to 68.13% after the issue.
- This is an SME issue. One lot is 1,200 shares, which is about Rs 1.27 lakh at the upper band of Rs 106, and SME shares usually trade in low volume after listing.
Source-provided company information. Read the RHP for the complete risk factors; these points are not a recommendation.
Listing performance
Actual listing figures appear after listing. Current gain is source-adjusted for corporate actions. CMP is a source snapshot, not a streaming quote.
Official documents, registrar & contacts
Offer documents
KFin Technologies Limited
Phone: 040-79615565
Email: himalaya.ipo@kfintech.com
Allotment date: 25 Sep 2026
- •Nirbhay Capital Services
Plot No. 101/A, Phase-III, Industrial Development Park, Cherlapally, Hindustan Cables Ltd, Uppal, Hyderabad, Telangana, 500051
Phone: +91-9063498493
Email: info@himalayanutravedics.com
Continue your IPO research
Explore more IPO companies
Related by issue type, with active issues first. These are research links, not investment recommendations.